“世界の核医学/放射性医薬品市場は、2023年の55億米ドルから2028年には94億米ドルに達すると予測され、予測期間中のCAGRは11.3%と展望”
核医学/放射性医薬品市場の成長の主な要因は、CVDの有病率の増加、医療改善のための政府の取り組み、老人人口の急速な増加、PETおよびSPECT技術の採用拡大などです。しかし、放射性医薬品の半減期が短いため、潜在的な採用率が低下し、市場の成長に一定の影響を及ぼすと予想されます。
“予測期間中、治療分野が最も高いCAGRで成長すると予測”
核医学/放射性医薬品市場はタイプ別に診断用と治療用に区分されます。予測期間中、最も高いCAGRで成長すると予測されるのは治療分野です。これは、これらのアイソトープが手術や化学療法とは対照的に副作用が少ないため、腫瘍学におけるこれらのアイソトープの用途が拡大していることに起因しています。
“エンドユーザー分野は病院が核医学/放射性医薬品市場で最大シェアを占めると予測”
エンドユーザー別では、核医学/放射性医薬品市場は病院、イメージングセンター、学術・研究センター、製薬/バイオテクノロジー企業や受託研究機関を含むその他のエンドユーザーに区分されます。2023年には、病院セグメントが核医学/放射性医薬品市場で最大のシェアを占めると予測されています。これは、患者ケアの質を向上させるために、放射線科患者のワークフローの自動化とデジタル化に注目が集まっているためです。
“地域別では、北米が核医学/放射性医薬品市場の最大シェアを占めると予測”
地域別では、北米が2023年の核医学/放射性医薬品市場で最大のシェアを占めるとされています。同地域では、慢性疾患の有病率が上昇し、診断・治療件数が増加する見込みであること、政府の資金援助、企業の取り組みなどの要因が挙げられます。
供給側一次インタビューの内訳
– 企業タイプ別: 企業タイプ別:Tier 1:64%、Tier 2:23%、Tier 3:13% - 役職別: Cレベル – 35%、ディレクタレベル – 25%、その他 – 40% - 地域別: 地域別:北米 42%、欧州 21%、APAC 26%、その他地域 11%
核医学/放射性医薬品市場に参入している有力企業には、GE HealthCare (US),Cardinal Health (US), Curium (France),Bayer AG (Germany), Lantheus Holdings, Inc.(US), Bracco Imaging S.p.A. (Italy), PharmaLogic Holdings Corp. (US), Eczacıbaşı-Monrol Nuclear Products (Turkey), NTP Radioisotopes SOC Ltd (South Africa), Nordion Inc.(Canada), Advanced Accelerator Applications (France), NorthStar Medical Radioisotopes (US), Eckert & Ziegler (Germany), Isotope JSC (Russia), Siemens Healthineers (Germany), Jubilant DraxImage,Inc. (Canada).などがあります。
調査範囲
本レポートでは、核医学/放射性医薬品市場をタイプ、用途、処置数、エンドユーザー、地域に基づいて調査しています。また、市場成長に影響を与える要因(促進要因、阻害要因、機会、課題など)を調査しています。市場の機会と課題を分析し、市場リーダーのための競争状況の詳細を提供します。さらに、個々の成長動向に関してミクロ市場を分析し、4つの主要地域とそれぞれの国に関して市場セグメントの収益を予測しています。
レポート購入の主な利点
本レポートは、様々なレベルの分析(業界動向、トップ企業の市場シェア、企業プロフィール)に焦点を当てており、これらを合わせて基本的な見解を形成し、競争環境、高成長地域とその促進要因、阻害要因、課題、機会を分析しています。本レポートは、既存企業だけでなく、新規参入企業や中小企業にとっても、市場の動向を把握し、より大きな市場シェアを獲得するのに役立ちます。
本レポートでは、以下の点について考察しています:
– 核医学/放射性医薬品市場の成長に影響を与える主な促進要因(対象疾患の発生率と有病率の増加、アルファ線免疫療法に基づく標的がん治療の開発、Mo-99の需給ギャップを縮小する取り組み)、阻害要因(放射性医薬品の短い半減期)、機会(神経学的用途における放射性医薬品の使用と新興国における高い成長機会)、課題(病院予算の削減と高い設備コスト)分析。
– 市場参入: 世界の核医学/放射性医薬品市場におけるトップ企業が提供する製品ポートフォリオに関する包括的な情報。本レポートでは、核医学/放射性医薬品市場をタイプ別、用途別、処置数別、エンドユーザー別、地域別に分析。
– 製品開発/イノベーション: 世界の核医学/放射性医薬品市場における今後の動向と製品発売に関する詳細な洞察。
– 市場開発: タイプ、用途、処置量、エンドユーザー、地域別の有利な新興市場に関する包括的情報。
– 市場の多様化: 世界の核医学/放射性医薬品市場における新製品や製品強化、成長地域、最近の開発、投資に関する詳細情報。
– 競争力の評価: 世界の核医学/放射性医薬品市場における主要企業の市場シェア、成長戦略、製品提供、競争上のリーダーシップマッピング、能力に関する詳細な評価。
10.1 INTRODUCTION 197
TABLE 223 NUCLEAR MEDICINE MARKET, BY REGION, 2021–2028 (USD MILLION) 197
10.2 NORTH AMERICA 197
10.2.1 NORTH AMERICA: IMPACT OF ECONOMIC RECESSION 198
FIGURE 28 NORTH AMERICA: NUCLEAR MEDICINE MARKET SNAPSHOT 199
TABLE 224 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 199
TABLE 225 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 200
TABLE 226 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 200
TABLE 227 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 200
TABLE 228 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 229 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 230 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 231 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 232 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 202
TABLE 233 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 234 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 203
TABLE 235 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 203
TABLE 236 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 203
TABLE 237 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 204
10.2.2 US 204
10.2.2.1 US to dominate North American nuclear medicine market during forecast period 204
TABLE 238 US: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 205
TABLE 239 US: NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 240 US: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 241 US: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 206
TABLE 242 US: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 206
TABLE 243 US: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 206
TABLE 244 US: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION) 207
TABLE 245 US: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION) 207
TABLE 246 US: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 207
TABLE 247 US: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 208
TABLE 248 US: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 208
TABLE 249 US: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 208
TABLE 250 US: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 209
TABLE 251 US: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 209
10.2.3 CANADA 209
10.2.3.1 Increasing initiatives for medical isotope development to support market growth 209
TABLE 252 CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 210
TABLE 253 CANADA: NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 210
TABLE 254 CANADA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 255 CANADA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 256 CANADA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 257 CANADA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 212
TABLE 258 CANADA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION) 212
TABLE 259 CANADA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION) 212
TABLE 260 CANADA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 213
TABLE 261 CANADA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 213
TABLE 262 CANADA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 213
TABLE 263 CANADA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 214
TABLE 264 CANADA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 214
TABLE 265 CANADA: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 214
10.3 EUROPE 215
10.3.1 EUROPE: IMPACT OF ECONOMIC RECESSION 215
TABLE 266 EUROPE: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 216
TABLE 267 EUROPE: NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 216
TABLE 268 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 216
TABLE 269 EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 217
TABLE 270 EUROPE: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 217
TABLE 271 EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 217
TABLE 272 EUROPE: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION) 218
TABLE 273 EUROPE: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION) 218
TABLE 274 EUROPE: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 218
TABLE 275 EUROPE: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 219
TABLE 276 EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 219
TABLE 277 EUROPE: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 219
TABLE 278 EUROPE: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 220
TABLE 279 EUROPE: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 220
10.3.2 GERMANY 220
10.3.2.1 Well-established healthcare system to drive market growth 220
TABLE 280 GERMANY: NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 221
TABLE 281 GERMANY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 222
TABLE 282 GERMANY: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 222
TABLE 283 GERMANY: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 222
TABLE 284 GERMANY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 223
TABLE 285 GERMANY: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION) 223
TABLE 286 GERMANY: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION) 223
TABLE 287 GERMANY: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 224
TABLE 288 GERMANY: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 224
TABLE 289 GERMANY: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 224
TABLE 290 GERMANY: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 225
TABLE 291 GERMANY: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 225
TABLE 292 GERMANY: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 225
10.3.3 FRANCE 226
10.3.3.1 Rising incidence of diseases such as cancer, Alzheimer’s, and Parkinson’s disease to favor market growth 226
TABLE 293 FRANCE: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 227
TABLE 294 FRANCE: NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 227
TABLE 295 FRANCE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 227
TABLE 296 FRANCE: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 228
TABLE 297 FRANCE: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 228
TABLE 298 FRANCE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 228
TABLE 299 FRANCE: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION) 229
TABLE 300 FRANCE: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION) 229
TABLE 301 FRANCE: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 229
TABLE 302 FRANCE: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 230
TABLE 303 FRANCE: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 230
TABLE 304 FRANCE: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 230
TABLE 305 FRANCE: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 231
TABLE 306 FRANCE: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 231
10.3.4 UK 231
10.3.4.1 Growing demand for diagnostic imaging and growing awareness to drive market growth 231
TABLE 307 UK: NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 232
TABLE 308 UK: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 232
TABLE 309 UK: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 233
TABLE 310 UK: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 233
TABLE 311 UK: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 233
TABLE 312 UK: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION) 234
TABLE 313 UK: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION) 234
TABLE 314 UK: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 234
TABLE 315 UK: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 235
TABLE 316 UK: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 235
TABLE 317 UK: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 235
TABLE 318 UK: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 236
TABLE 319 UK: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 236
10.3.5 ITALY 236
10.3.5.1 Rising geriatric population to support market growth 236
TABLE 320 ITALY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 237
TABLE 321 ITALY: NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 237
TABLE 322 ITALY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 237
TABLE 323 ITALY: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 238
TABLE 324 ITALY: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 238
TABLE 325 ITALY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 238
TABLE 326 ITALY: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION) 239
TABLE 327 ITALY: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION) 239
TABLE 328 ITALY: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 239
TABLE 329 ITALY: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 240
TABLE 330 ITALY: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 240
TABLE 331 ITALY: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 240
TABLE 332 ITALY: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 241
TABLE 333 ITALY: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 241
10.3.6 SPAIN 241
10.3.6.1 Increasing initiatives by SEMNIM to drive growth 241
TABLE 334 SPAIN: NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 242
TABLE 335 SPAIN: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 242
TABLE 336 SPAIN: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 242
TABLE 337 SPAIN: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 243
TABLE 338 SPAIN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 243
TABLE 339 SPAIN: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION) 243
TABLE 340 SPAIN: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION) 244
TABLE 341 SPAIN: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 244
TABLE 342 SPAIN: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 244
TABLE 343 SPAIN: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 245
TABLE 344 SPAIN: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 245
TABLE 345 SPAIN: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 245
TABLE 346 SPAIN: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 246
10.3.7 REST OF EUROPE 246
TABLE 347 REST OF EUROPE: NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 247
TABLE 348 REST OF EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 247
TABLE 349 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 247
TABLE 350 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 248
TABLE 351 REST OF EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 248
TABLE 352 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION) 248
TABLE 353 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION) 249
TABLE 354 REST OF EUROPE: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 249
TABLE 355 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 249
TABLE 356 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 250
TABLE 357 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 250
TABLE 358 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 250
TABLE 359 REST OF EUROPE: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 251
10.4 ASIA PACIFIC 251
10.4.1 ASIA PACIFIC: IMPACT OF ECONOMIC RECESSION 251
FIGURE 29 ASIA PACIFIC: NUCLEAR MEDICINE MARKET SNAPSHOT (2022) 252
TABLE 360 ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 252
TABLE 361 ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 253
TABLE 362 ASIA PACIFIC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 253
TABLE 363 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 253
TABLE 364 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 254
TABLE 365 ASIA PACIFIC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 254
TABLE 366 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION) 254
TABLE 367 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION) 255
TABLE 368 ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 255
TABLE 369 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 255
TABLE 370 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 256
TABLE 371 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 256
TABLE 372 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 256
TABLE 373 ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 257
10.4.2 JAPAN 257
10.4.2.1 Japan to dominate APAC nuclear medicine market 257
TABLE 374 JAPAN: NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 258
TABLE 375 JAPAN: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 258
TABLE 376 JAPAN: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 258
TABLE 377 JAPAN: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 259
TABLE 378 JAPAN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 259
TABLE 379 JAPAN: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION) 259
TABLE 380 JAPAN: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION) 260
TABLE 381 JAPAN: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 260
TABLE 382 JAPAN: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 260
TABLE 383 JAPAN: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 261
TABLE 384 JAPAN: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 261
TABLE 385 JAPAN: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 261
TABLE 386 JAPAN: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 262
10.4.3 CHINA 262
10.4.3.1 Increasing nuclear medicine infrastructure and growing prevalence of chronic diseases to augment market 262
TABLE 387 CHINA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 263
TABLE 388 CHINA: NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 263
TABLE 389 CHINA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 263
TABLE 390 CHINA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 264
TABLE 391 CHINA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 264
TABLE 392 CHINA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 264
TABLE 393 CHINA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION) 265
TABLE 394 CHINA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION) 265
TABLE 395 CHINA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 265
TABLE 396 CHINA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 266
TABLE 397 CHINA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 266
TABLE 398 CHINA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 266
TABLE 399 CHINA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 267
TABLE 400 CHINA: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 267
10.4.4 REST OF ASIA PACIFIC 267
TABLE 401 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 268
TABLE 402 REST OF ASIA PACIFIC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 269
TABLE 403 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 269
TABLE 404 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 269
TABLE 405 REST OF ASIA PACIFIC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 270
TABLE 406 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION) 270
TABLE 407 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION) 270
TABLE 408 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 271
TABLE 409 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 271
TABLE 410 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 271
TABLE 411 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 272
TABLE 412 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 272
TABLE 413 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 272
10.5 REST OF THE WORLD 273
10.5.1 REST OF THE WORLD: IMPACT OF ECONOMIC RECESSION 274
TABLE 414 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 274
TABLE 415 REST OF THE WORLD: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 275
TABLE 416 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 275
TABLE 417 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 275
TABLE 418 REST OF THE WORLD: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 276
TABLE 419 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION) 276
TABLE 420 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION) 276
TABLE 421 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 277
TABLE 422 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 277
TABLE 423 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 277
TABLE 424 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 278
TABLE 425 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 278
TABLE 426 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 278
11 COMPETITIVE LANDSCAPE 279
11.1 INTRODUCTION 279
11.2 STRATEGIES ADOPTED BY KEY PLAYERS 279
TABLE 427 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 279
11.3 MARKET RANKING ANALYSIS 281
FIGURE 30 NUCLEAR MEDICINE MARKET: MARKET RANKING, 2022 281
11.4 REVENUE ANALYSIS OF KEY MARKET PLAYERS 282
FIGURE 31 REVENUE SHARE ANALYSIS OF KEY PLAYERS 282
11.5 COMPANY EVALUATION MATRIX 283
11.5.1 STARS 283
11.5.2 EMERGING LEADERS 283
11.5.3 PERVASIVE PLAYERS 283
11.5.4 PARTICIPANTS 283
FIGURE 32 NUCLEAR MEDICINE MARKET: COMPANY EVALUATION MATRIX (2021) 284
11.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES 285
11.6.1 PROGRESSIVE COMPANIES 285
11.6.2 STARTING BLOCKS 285
11.6.3 RESPONSIVE COMPANIES 285
11.6.4 DYNAMIC COMPANIES 285
FIGURE 33 NUCLEAR MEDICINE MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES 286
11.7 COMPETITIVE BENCHMARKING 287
11.7.1 OVERALL FOOTPRINT OF KEY PLAYERS 287
TABLE 428 OVERALL FOOTPRINT OF KEY PLAYERS 287
TABLE 429 REGIONAL FOOTPRINT OF KEY PLAYERS 287
TABLE 430 TYPE FOOTPRINT OF KEY PLAYERS 287
11.8 COMPETITIVE SCENARIO 288
11.8.1 PRODUCT APPROVALS & ENHANCEMENTS 288
TABLE 431 KEY PRODUCT APPROVALS & ENHANCEMENTS 288
11.8.2 DEALS 289
TABLE 432 KEY DEALS 289
11.8.3 OTHER DEVELOPMENTS 292
TABLE 433 KEY OTHER DEVELOPMENTS 292
12 COMPANY PROFILES 294
12.1 MAJOR PLAYERS 294
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 GE HEALTHCARE 294
TABLE 434 GE HEALTHCARE: BUSINESS OVERVIEW 294
FIGURE 34 GE HEALTHCARE: COMPANY SNAPSHOT (2022) 295
12.1.2 CARDINAL HEALTH 298
TABLE 435 CARDINAL HEALTH: BUSINESS OVERVIEW 298
FIGURE 35 CARDINAL HEALTH: COMPANY SNAPSHOT (2022) 299
12.1.3 CURIUM 301
TABLE 436 CURIUM: BUSINESS OVERVIEW 301
12.1.4 BAYER AG 305
TABLE 437 BAYER AG: BUSINESS OVERVIEW 305
FIGURE 36 BAYER AG: COMPANY SNAPSHOT (2021) 305
12.1.5 LANTHEUS HOLDINGS, INC. 308
TABLE 438 LANTHEUS HOLDINGS, INC.: BUSINESS OVERVIEW 308
FIGURE 37 LANTHEUS HOLDINGS, INC.: COMPANY SNAPSHOT (2021) 309
12.1.6 BRACCO IMAGING S.P.A. 312
TABLE 439 BRACCO IMAGING S.P.A.: BUSINESS OVERVIEW 312
12.1.7 PHARMALOGIC HOLDINGS CORP. 314
TABLE 440 PHARMALOGIC HOLDINGS CORP.: BUSINESS OVERVIEW 314
12.1.8 ECZACIBAŞI-MONROL NUCLEAR PRODUCTS 316
TABLE 441 ECZACIBAŞI-MONROL NUCLEAR PRODUCTS: BUSINESS OVERVIEW 316
12.1.9 NTP RADIOISOTOPES SOC LTD. (A SUBSIDIARY OF SOUTH AFRICAN NUCLEAR ENERGY CORPORATION) 319
TABLE 442 NTP RADIOISOTOPES SOC LTD.: BUSINESS OVERVIEW 319
12.1.10 NORDION INC. 321
TABLE 443 NORDION INC.: BUSINESS OVERVIEW 321
12.1.11 ADVANCED ACCELERATOR APPLICATIONS (A NOVARTIS COMPANY) 323
TABLE 444 ADVANCED ACCELERATOR APPLICATIONS: BUSINESS OVERVIEW 323
12.1.12 NORTHSTAR MEDICAL RADIOISOTOPES 325
TABLE 445 NORTHSTAR MEDICAL RADIOISOTOPES: BUSINESS OVERVIEW 325
12.1.13 ECKERT & ZIEGLER 328
TABLE 446 ECKERT & ZIEGLER: BUSINESS OVERVIEW 328
FIGURE 38 ECKERT & ZIEGLER: COMPANY SNAPSHOT (2021) 329
12.1.14 ISOTOPE JSC 333
TABLE 447 JOINT STOCK COMPANY ISOTOPE (ISOTOPE JSC): BUSINESS OVERVIEW 333
12.1.15 SIEMENS HEALTHINEERS 335
TABLE 448 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW 335
FIGURE 39 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2022) 336
12.1.16 JUBILANT DRAXIMAGE, INC. (A SUBSIDIARY OF JUBILANT PHARMA) 338
TABLE 449 JUBILANT DRAXIMAGE, INC.: BUSINESS OVERVIEW 338
12.2 OTHER PLAYERS 341
12.2.1 GLOBAL MEDICAL SOLUTIONS 341
12.2.2 SHINE TECHNOLOGIES, LLC 342
12.2.3 ISOTOPIA MOLECULAR IMAGING LTD. 343
12.2.4 BWXT MEDICAL LTD. 344
12.2.5 INSTITUTE OF ISOTOPES 345
12.2.6 CHINA ISOTOPE & RADIATION CORPORATION 346
12.2.7 YANTAI DONGCHENG PHARMACEUTICAL GROUP CO., LTD. 347
12.2.8 CYCLOPHARM 347
12.2.9 IRE ELIT 348
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 349
13.1 DISCUSSION GUIDE 349
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 356
13.3 CUSTOMIZATION OPTIONS 358
13.4 RELATED REPORTS 358
13.5 AUTHOR DETAILS 359
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/